Biotech startup Irubis has closed a €2.8 million seed funding round. The company aims to automate process development and manufacturing of biopharmaceutical drugs and has developed a technology that is a plug-and-play system that simplifies automated measurement of metabolites and nutrients in cell cultivation and protein quantity and quality parameters in purification. Investors are High-Tech Gründerfonds (HTGF), Verve Ventures and Ventura BioMed as well as EIC Fund, the Initiative for Industrial Innovators and other business angels from the biotech industry or the Munich startup scene.
Irubis innovative process analytical technology (PAT) Monipa, is based on mid infrared spectroscopy. The real-time monitoring system has been developed in close partnership with biopharma companies. The plug-and-play system simplifies the prediction of metabolites and nutrients in cell cultivations and protein quantity and quality parameters in purification. Process monitoring and control enables higher yield, better quality and shortens the overall process development.
“This seed financing round boosts our mission of making spectroscopy the state of the art in real-time process monitoring. The fresh capital enables us to scale, grow our team, increase sales and introduce the next Monipa version to the market.”
Anja Müller, Co-Founder of IRUBIS
“Sensitive and robust measurements without the need for additional time-consuming calibration are a long-sought necessity for the production of biopharmaceutical drugs. IRUBIS fills this need with their innovative and reliable Monipa technology. Together with our co-investors we are excited to the scale-up happening in the next year.”
Dr. Laura Pedroza, Investment Manager at High-Tech Gründerfonds
Irubis was founded in September 2017 by Lorenz Sykora-Mirle, Alexander Geißler and Anja Müller with the goal to automate the process development and manufacturing of biopharmaceutical drugs.